A5069191381- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Pelvic floor disorders treatments
- Anorectal Disease Treatments and Outcomes
- Cancer, Lipids, and Metabolism
- Phagocytosis and Immune Regulation
- Pelvic and Acetabular Injuries
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease and Transplantation
- Colorectal Cancer Screening and Detection
- Lung Cancer Research Studies
- Fibroblast Growth Factor Research
- Kruppel-like factors research
- Neuroendocrine Tumor Research Advances
- Cancer Research and Treatments
- Diverticular Disease and Complications
- Lung Cancer Treatments and Mutations
- Liver physiology and pathology
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Glioma Diagnosis and Treatment
National Cheng Kung University Hospital
2011-2023
Singapore General Hospital
2020
Imperial College London
2016-2017
Chelsea and Westminster Hospital
2017
Hammersmith Hospital
2016-2017
Chelsea and Westminster Hospital NHS Foundation Trust
2017
Kyungpook National University
2011
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and has high mortality despite treatment. While sorafenib a survival benefit for patients with advanced HCC, clinical response highly variable.To determine whether development of toxicity prognostic marker in HCC.In this prospective multicentre cohort study, advanced-stage HCC receiving were recruited from five international specialist centres. Demographic data including grade during treatment, radiological to time...
Summary Background Drug development in hepatocellular carcinoma ( HCC ) is limited by disease heterogeneity, with hepatic reserve being a major source of variation survival outcomes. The albumin–bilirubin ALBI grade validated index liver function patients . Aim To test the accuracy predicting post‐sorafenib overall PSOS who permanently discontinued treatment. Methods From prospectively maintained international database 447 consecutive referrals, we derived 386 eligible treated sorafenib...
<b><i>Background:</i></b> Level I evidence supports the use of sorafenib in patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma, where heterogeneity efficacy exists due to varying clinicopathologic features disease. <b><i>Aim:</i></b> We evaluated whether prior treatment curative or locoregional therapies influences sorafenib-specific survival. <b><i>Methods:</i></b> From a prospective...
Introduction This study aimed to ascertain whether missed obstetric anal sphincter injury at delivery had worse functional and quality of life outcomes than primary repair immediately following delivery. Materials methods Two one propensity matching was undertaken patients presenting a tertiary pelvic floor unit with ultrasound evidence within 24 months who underwent the time by parity, grade assessment. Outcomes compared included Birmingham Bowel, Bladder Urinary Symptom Questionnaire...
The aim of this study was to compare functional and quality life data in patients with increasing grades obstetric anal sphincter injury (OASI) presenting a tertiary colorectal pelvic floor clinic within 24 months delivery. Prospective were collected from the for period 2009–2016 included on outcomes motor anorectal manometry parameters. instruments used evaluation Birmingham Bowel Urinary Symptoms Questionnaire, Wexner Incontinence Score, Short Form 36, Pelvic Organ Prolapse/Urinary Sexual...
Background: Colorectal Cancer (CRC) is a disease of the elderly, and with an ageing population, oncological surgical procedures for CRC in elderly expected to increase. However, balance between benefits risks associated age comorbidities patients obscure.Materials methods: A retrospective database consecutive who received surgery was used compare short-term outcomes aged ≥75 <75 years old undergoing resection.Results: There were 54 (63.5%) group 31 (36.5%) group. Overall, there no...